EmeraNova™ Expands Access to Wound Imaging, Supporting Clinical Diagnostic Capabilities

PHOENIX — Following yesterday’s milestone launch announcement, EmeraNova™, the new corporate identity of BioLab Holdings and a medical technology company building an advanced tissue restoration platform, has announced a collaboration that will expand its portfolio into an entirely new category and allow it to enter additional care settings. Technology leader Kent Imaging is teaming up with EmeraNova to bring advanced wound imaging to wound care clinics, surgical centers, hospitals and HOPDs.

“This collaboration with Kent Imaging is a proof point of the direction we’re headed.”

“This collaboration with Kent Imaging is a proof point of the direction we’re headed,” said EmeraNova President & CEO Jaime Leija. “Not only are we expanding the diagnostic category of our toolbox of products, a crucial step in the tissue restoration journey, but these technologies will allow us to aid clinicians’ ability to make diagnoses in a much wider range of care settings, providing a deeper, more advanced look into a patient issue.”

Kent Imaging’s SnapshotNIR and SnapshotGLO work together to reveal two key barriers to repair—low tissue oxygenation and elevated bacterial bioburden. With dual imaging insights, clinicians gain clarity, confidence, and speed in decision-making, supporting earlier, more targeted interventions that optimize treatment and reduce delays.

SnapshotNIR is non-invasive, cost effective, and measures and reports approximate values of tissue oxygen saturation (StO2), relative oxyhemoglobin, relative deoxyhemoglobin in superficial tissue. SnapshotGLO is an adjunctive tool that uses ultraviolet light via a handheld portable device to provide users with a visual of elevated bacterial loads in a wound by detecting fluorescence emitted from bacteria at loads greater than 10⁴ CFU/g*.

“The strongest clinical decisions begin with a clearer understanding of what is happening beneath and around a wound,” said Pierre Lemire, CEO of Kent Imaging. “Partnering with EmeraNova allows us to pair advanced imaging insights with a broader tissue restoration strategy, helping clinicians connect assessment to next steps with greater confidence.”

The collaboration reflects EmeraNova’s continued strategy of building one of the industry’s most comprehensive tissue restoration toolboxes through partnerships with companies developing advanced regenerative, imaging and therapeutic technologies. Through its commercialization network, EmeraNova will support broader adoption of Kent Imaging’s technologies across care settings nationwide.

For more information on EmeraNova’s toolbox of tissue restoration products, visit emeranova.com.

EmeraNova™ is a leading medical technology company advancing tissue restoration across healing phases, care settings, and specialties by building a global platform that identifies promising technologies from around the world and accelerates their path into clinical practice. Through an expanding toolbox of tissue restoration solutions, world-class support, and a commitment to bringing together expert voices and clinical insights, EmeraNova aims to help shape what’s possible in tissue repair. BLS Labs, LLC and BLS Sales & Marketing, LLC, are accredited by the Association for Advancing Tissue and Biologics (AATB), reflecting the organization’s commitment to rigorous standards for quality, safety and operational excellence. For more information, visit emeranova.com.

Based in Calgary, Alberta, Canada, Kent Imaging is a leading innovator in advanced imaging technology. The company designs, manufactures, and markets medical devices that support real-time decision-making in wound care, vascular, and surgical specialties. Through patented technologies, Kent continues to deliver groundbreaking solutions that support healthcare systems around the world.

The Snapshot product suite now includes two powerful imaging devices: SnapshotNIR, a near-infrared tissue oxygenation imaging device initially cleared by the FDA and Health Canada in 2017 and CE-marked in 2025; and SnapshotGLO, a bacterial autofluorescence imaging device that received FDA 510(k) clearance in 2025. SnapshotNIR is supported by clinical evidence demonstrating its role in enhancing clinical decision-making, while SnapshotGLO provides real-time insight into wound bioburden presence and distribution. Together, the Snapshot product family strengthens clinicians’ ability to detect, direct, and protect—promoting treatment consistency, supporting improved workflow, and contributing to better patient care worldwide.

SnapshotGLO® is a registered trademark of Kent Imaging Inc.

SnapshotNIR® is a registered trademark of Kent Imaging Inc.

Contacts

: Kwyn Lowe

: 406.314.5120

: